Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
6 Jul 2021

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types

Dr Christophe Massard and Prof Eva Compérat
FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types ( Dr Christophe Massard and Prof Eva Compérat )
1 Jul 2021

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA
ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )
29 Jun 2021

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )
29 Jun 2021

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM

Prof Thierry Facon - Chu De Lille, Lille, France
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )
25 Jun 2021

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Dr Claudio Cerchione - IRCCS, Meldola, Italy
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )
23 Jun 2021

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )
22 Jun 2021

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021